{
  "id": 19571107,
  "title": "Xenon at Stifel 2026 healthcare conference: epilepsy launch in focus",
  "url": "https://urgent.news/2026/11/11/xenon-at-stifel-2026-healthcare-conference-epilepsy-launch-in-focus",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-11T23:21:16.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/xenon-at-stifel-2026-healthcare-conference-epilepsy-launch-in-focus-93CH-5020058"
  },
  "original_language": "en",
  "account": "Xenon Pharmaceuticals (XENE) used its appearance at the Stifel 2026 Healthcare Conference on 11 November 2026 to outline a strategy centered on azetukalner for epilepsy, potential expansion into psychiatry and an expanding pain pipeline. Management expressed confidence in the lead epilepsy program, acknowledging uncertainty surrounding upcoming depression data and the risks of drug development. The azetukalner NDA for focal seizure epilepsy is on track for possible launch in early 2028, following positive Phase III data. Xenon plans to unblind its first Phase III major depressive disorder study, X-NOVA2, in December after a voluntary pause in September. Pain candidates XEN1701 and XEN1120, both meeting Phase I goals, are expected to move into Phase II proof-of-concept studies in 2025. The company ended Q3 2024 with $1.2 billion in cash, projected to last through 2029. Management described the company as preparing for a conservative epilepsy launch curve, believing azetukalner's profile could enable faster market share gain than older anti-seizure drugs.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}